Ultra Low Dose CT and Use of Iomeron 400 in PCD-CT

Condition(s) studied

Investigational drug(s) / intervention(s)

Computed Tomography: Computed Tomography CHEST

Study summary

Evaluation of ultra low dose protocols and Iomeron 400 contrast in PCD-CT

Eligibility

Primary outcome measure(s)

• Dose Reduction by new scanner — through study completion, an average of 1 year
  mSv per exam will be recorded. This value will be put in correlation to weight (Kg), height (cm) and BMI.
• stable Image Quality in reduced dose scans — through study completion, an average of 1 year
  Recorded values compared in 2 populations-different contrast agents by using qualitative\&quantitative methods Qualitative:diagnostic certainty, assessability of lung structure/lesions,diagnostic reliability, Quantitative:Assessment of tissue composition,diagnostic performance measurements Attenuation/sealing measurement (HU), signal-to-noise ratio (SNR), contrast-to-noise ratio ,size dimensions of lung structure/lesion in three dimensions in millimeters Tissue composition assessment diagnostic performance measurements (sensitivity, specificity, accuracy) diagnostic confidence: 1-4 Theses measurements will be put in correlation to the scan dose (mSv) per patient, forming two groups with matched BMI (kg/m\^2)

Trial sites (1)

More University of Zurich trials in Switzerland

Other trials for the same condition